USE OF ANTICOAGULANTS IN CEREBRAL VASCULAR PATHOLOGY
CRISTINA FLORENTINA PLEȘA 1, CAMELIA NICOLAE 2*, CARMEN ADELLA SÎRBU 1, ROXANA NEMEȘ 1, ALINA PĂUNESCU 3, MONICA MARILENA ȚÂNȚU 3
1Central Universitary Emergency Military Hospital “Carol Davila”, Department of neurology, Calea Plevnei Street 134,
Bucharest, Romania
2”Carol Davila” University of Medicine and Pharmacy, Dionisie Lupu 37, Bucharest, Romania
3University of Piteşti, Faculty of Sciences, Department of Medical Care Assistance and Kinesiotherapy, Târgu din Vale 1,
Piteşti, Romania
*corresponding author: dr_camelia_nicolae@yahoo.com
Download Full Article

Abstract:
The aetiology of ischemic vascular stroke (IVS) is various, the most common cause being cardioembolic, and anticoagulation
treatment plays an essential role in the prevention of cerebral ischemic events. Atrial fibrillation (AF) is the pathological
condition requiring long-term anticoagulant therapy for preventive purposes, both primary and secondary. Complications,
disabilities and mortality are more common in patients who had an ischemic stroke associated with atrial fibrillation than in
those without AF. The indication, type and dose of anticoagulant depend on the stage and size of the ischemic lesion,
thromboembolic and haemorrhagic risk and patient compliance. According to the 2018 European Heart Rhythm Association
Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation, among the
different types of anticoagulants indicated in the case of AF and IS, it would be preferable to use new anticoagulants.
Anticoagulation medication is indicated in the acute stage only in patients with a clear thromboembolic source. Anticoagulant
treatment has a well-established role over time as a result of numerous clinical trials, its use having a guide recommendation,
but the particularity of each case as well as personal experience strengthens the indication.

Top